IFN-γ signalling was inhibited by protein tyrosine phosphatase non-receptor type 2 (PTPN2) whose deletion in tumour cells increased ICBT efficacy by enhancing IFN-γ-mediated effects on antigen presentation and cell growth inhibition [68]. The gene discussed is PTPN2; the disease is neoplasm.